148 related articles for article (PubMed ID: 34880877)
1. Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report.
Ye Y; Zheng S
Front Immunol; 2021; 12():785400. PubMed ID: 34880877
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer.
Wei T; Zhang Q; Li X; Su W; Li G; Ma T; Gao S; Lou J; Que R; Zheng L; Bai X; Liang T
Mol Cancer Ther; 2019 Jan; 18(1):196-203. PubMed ID: 30301865
[TBL] [Abstract][Full Text] [Related]
4. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Du J; Gu J; Li J
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
[TBL] [Abstract][Full Text] [Related]
6. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
7. Response in
Campoverde LE; Batalini F; Bulushi Y; Bullock A
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
[TBL] [Abstract][Full Text] [Related]
8. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.
Park R; Al-Jumayli M; Miller K; Saeed A; Saeed A
Cancer Treat Res Commun; 2021; 27():100342. PubMed ID: 33611092
[TBL] [Abstract][Full Text] [Related]
9. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
10. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.
Singh H; Perez K; Wolpin BM; Aguirre AJ
J Clin Oncol; 2021 Oct; 39(29):3199-3206. PubMed ID: 34428095
[No Abstract] [Full Text] [Related]
11. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
[TBL] [Abstract][Full Text] [Related]
12. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Ascorbate Enhances Chemotherapies in Pancreatic Ductal Adenocarcinoma.
O'Leary BR; Ruppenkamp EK; Steers GJ; Du J; Carroll RS; Wagner BA; Buettner GR; Cullen JJ
Pancreas; 2022 Jul; 51(6):684-693. PubMed ID: 36099493
[TBL] [Abstract][Full Text] [Related]
14. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Hu ZI; Hellmann MD; Wolchok JD; Vyas M; Shia J; Stadler ZK; Diaz LA; O'Reilly EM
J Immunother Cancer; 2018 Nov; 6(1):127. PubMed ID: 30458888
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous regression of pancreatic cancer with liver metastases.
Saade Lemus P; Anderson K; Smith M; Bullock A
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31154349
[TBL] [Abstract][Full Text] [Related]
18. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
[TBL] [Abstract][Full Text] [Related]
19. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
20. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
